Page last updated: 2024-11-07

uh-ah 37

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

UH-AH 37: an ileal-selective muscarinic antagonist; RN from Toxlit [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID129140
SCHEMBL ID6746859
MeSH IDM0166520

Synonyms (7)

Synonym
uh-ah 37
1-chloro-11-[2-(1-methylpiperidin-4-yl)acetyl]-5h-benzo[b][1,4]benzodiazepin-6-one
(+)-6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)-acetyl]-11h-dibenzo[b,e][1,4]diazepin-11-one
UFJWXHOFKIGIAF-UHFFFAOYSA-N
SCHEMBL6746859
gtpl8583
Q27089076
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID1345286Human M1 receptor (Acetylcholine receptors (muscarinic))1998European journal of pharmacology, May-22, Volume: 349, Issue:2-3
Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))1991British journal of pharmacology, Jan, Volume: 102, Issue:1
Selectivity profile of the novel muscarinic antagonist UH-AH 37 determined by the use of cloned receptors and isolated tissue preparations.
AID1345343Human M3 receptor (Acetylcholine receptors (muscarinic))1991British journal of pharmacology, Jan, Volume: 102, Issue:1
Selectivity profile of the novel muscarinic antagonist UH-AH 37 determined by the use of cloned receptors and isolated tissue preparations.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))1998European journal of pharmacology, May-22, Volume: 349, Issue:2-3
Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists.
AID1345543Human M5 receptor (Acetylcholine receptors (muscarinic))1991British journal of pharmacology, Jan, Volume: 102, Issue:1
Selectivity profile of the novel muscarinic antagonist UH-AH 37 determined by the use of cloned receptors and isolated tissue preparations.
AID1345286Human M1 receptor (Acetylcholine receptors (muscarinic))1991British journal of pharmacology, Jan, Volume: 102, Issue:1
Selectivity profile of the novel muscarinic antagonist UH-AH 37 determined by the use of cloned receptors and isolated tissue preparations.
AID1345465Human M4 receptor (Acetylcholine receptors (muscarinic))1998European journal of pharmacology, May-22, Volume: 349, Issue:2-3
Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists.
AID1345465Human M4 receptor (Acetylcholine receptors (muscarinic))1991British journal of pharmacology, Jan, Volume: 102, Issue:1
Selectivity profile of the novel muscarinic antagonist UH-AH 37 determined by the use of cloned receptors and isolated tissue preparations.
AID1345343Human M3 receptor (Acetylcholine receptors (muscarinic))1998European journal of pharmacology, May-22, Volume: 349, Issue:2-3
Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists.
AID1345543Human M5 receptor (Acetylcholine receptors (muscarinic))1998European journal of pharmacology, May-22, Volume: 349, Issue:2-3
Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (16.67)18.7374
1990's4 (66.67)18.2507
2000's1 (16.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]